Molecular foundations for personalized therapy in prostate cancer

Kurt W. Fisher, Rodolfo Montironi, Antonio Lopez Beltran, Holger Moch, Lisha Wang, Marina Scarpelli, Sean R. Williamson, Michael Koch, Liang Cheng

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Prostate cancer is the most common and second most lethal cancer in men. The majority of prostate cancers are histologically similar to acinar adenocarcinomas and rely on androgen-dependent signaling for their development and progression. Androgen deprivation therapy is a mainstay of treatment regimens and we discuss the recent advancements in androgen-deprivation therapy. Recent advances in defining the genetic landscape of prostate cancer have shown that the depth of genetic heterogeneity surpasses what can be seen histologically and has the ability to redefine treatments. TMPRSS2-ETS family fusion proteins are unique to prostate cancer and we discuss their role in carcinogenesis, prognosis, and the development of TMPRSS2-ETS family gene fusion targeted therapy. Inactivation of the tumor suppressor PTEN leads to activation of the PI3K/Akt/mTOR pathway and we discuss the prognostic and treatment implications. Molecular genetic analysis has recently demonstrated that clinically aggressive high grade neuroendocrine prostate carcinomas contain a high prevalence of overexpression of Aurora A kinase and N-myc. We discuss the role of Aurora A kinase and N-myc in the development of the aggressive neuroendocrine phenotype and the development of targeted inhibitors of this specific genetic subtype. Lastly, we briefly discuss emerging genetic subtypes defined by either SPINK1 overexpression, CHD1 inactivation, or SPOP mutations. By reviewing the associations between the morphologic features and the molecular genetics of prostate cancer we hope to provide insight and guidance to the emerging options for targeted therapy.

Original languageEnglish (US)
Pages (from-to)103-114
Number of pages12
JournalCurrent Drug Targets
Volume16
Issue number2
StatePublished - 2015

Fingerprint

Aurora Kinase A
Androgens
Prostatic Neoplasms
Fusion reactions
Phosphatidylinositol 3-Kinases
Tumors
Therapeutics
Genes
Chemical activation
Molecular Biology
Neuroendocrine Carcinoma
Aptitude
Genetic Heterogeneity
Gene Fusion
Proteins
Prostate
Neoplasms
Carcinogenesis
Adenocarcinoma
Phenotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fisher, K. W., Montironi, R., Lopez Beltran, A., Moch, H., Wang, L., Scarpelli, M., ... Cheng, L. (2015). Molecular foundations for personalized therapy in prostate cancer. Current Drug Targets, 16(2), 103-114.

Molecular foundations for personalized therapy in prostate cancer. / Fisher, Kurt W.; Montironi, Rodolfo; Lopez Beltran, Antonio; Moch, Holger; Wang, Lisha; Scarpelli, Marina; Williamson, Sean R.; Koch, Michael; Cheng, Liang.

In: Current Drug Targets, Vol. 16, No. 2, 2015, p. 103-114.

Research output: Contribution to journalArticle

Fisher, KW, Montironi, R, Lopez Beltran, A, Moch, H, Wang, L, Scarpelli, M, Williamson, SR, Koch, M & Cheng, L 2015, 'Molecular foundations for personalized therapy in prostate cancer', Current Drug Targets, vol. 16, no. 2, pp. 103-114.
Fisher KW, Montironi R, Lopez Beltran A, Moch H, Wang L, Scarpelli M et al. Molecular foundations for personalized therapy in prostate cancer. Current Drug Targets. 2015;16(2):103-114.
Fisher, Kurt W. ; Montironi, Rodolfo ; Lopez Beltran, Antonio ; Moch, Holger ; Wang, Lisha ; Scarpelli, Marina ; Williamson, Sean R. ; Koch, Michael ; Cheng, Liang. / Molecular foundations for personalized therapy in prostate cancer. In: Current Drug Targets. 2015 ; Vol. 16, No. 2. pp. 103-114.
@article{df7227ab74be49ba844fe5a2aa2b31d0,
title = "Molecular foundations for personalized therapy in prostate cancer",
abstract = "Prostate cancer is the most common and second most lethal cancer in men. The majority of prostate cancers are histologically similar to acinar adenocarcinomas and rely on androgen-dependent signaling for their development and progression. Androgen deprivation therapy is a mainstay of treatment regimens and we discuss the recent advancements in androgen-deprivation therapy. Recent advances in defining the genetic landscape of prostate cancer have shown that the depth of genetic heterogeneity surpasses what can be seen histologically and has the ability to redefine treatments. TMPRSS2-ETS family fusion proteins are unique to prostate cancer and we discuss their role in carcinogenesis, prognosis, and the development of TMPRSS2-ETS family gene fusion targeted therapy. Inactivation of the tumor suppressor PTEN leads to activation of the PI3K/Akt/mTOR pathway and we discuss the prognostic and treatment implications. Molecular genetic analysis has recently demonstrated that clinically aggressive high grade neuroendocrine prostate carcinomas contain a high prevalence of overexpression of Aurora A kinase and N-myc. We discuss the role of Aurora A kinase and N-myc in the development of the aggressive neuroendocrine phenotype and the development of targeted inhibitors of this specific genetic subtype. Lastly, we briefly discuss emerging genetic subtypes defined by either SPINK1 overexpression, CHD1 inactivation, or SPOP mutations. By reviewing the associations between the morphologic features and the molecular genetics of prostate cancer we hope to provide insight and guidance to the emerging options for targeted therapy.",
author = "Fisher, {Kurt W.} and Rodolfo Montironi and {Lopez Beltran}, Antonio and Holger Moch and Lisha Wang and Marina Scarpelli and Williamson, {Sean R.} and Michael Koch and Liang Cheng",
year = "2015",
language = "English (US)",
volume = "16",
pages = "103--114",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Molecular foundations for personalized therapy in prostate cancer

AU - Fisher, Kurt W.

AU - Montironi, Rodolfo

AU - Lopez Beltran, Antonio

AU - Moch, Holger

AU - Wang, Lisha

AU - Scarpelli, Marina

AU - Williamson, Sean R.

AU - Koch, Michael

AU - Cheng, Liang

PY - 2015

Y1 - 2015

N2 - Prostate cancer is the most common and second most lethal cancer in men. The majority of prostate cancers are histologically similar to acinar adenocarcinomas and rely on androgen-dependent signaling for their development and progression. Androgen deprivation therapy is a mainstay of treatment regimens and we discuss the recent advancements in androgen-deprivation therapy. Recent advances in defining the genetic landscape of prostate cancer have shown that the depth of genetic heterogeneity surpasses what can be seen histologically and has the ability to redefine treatments. TMPRSS2-ETS family fusion proteins are unique to prostate cancer and we discuss their role in carcinogenesis, prognosis, and the development of TMPRSS2-ETS family gene fusion targeted therapy. Inactivation of the tumor suppressor PTEN leads to activation of the PI3K/Akt/mTOR pathway and we discuss the prognostic and treatment implications. Molecular genetic analysis has recently demonstrated that clinically aggressive high grade neuroendocrine prostate carcinomas contain a high prevalence of overexpression of Aurora A kinase and N-myc. We discuss the role of Aurora A kinase and N-myc in the development of the aggressive neuroendocrine phenotype and the development of targeted inhibitors of this specific genetic subtype. Lastly, we briefly discuss emerging genetic subtypes defined by either SPINK1 overexpression, CHD1 inactivation, or SPOP mutations. By reviewing the associations between the morphologic features and the molecular genetics of prostate cancer we hope to provide insight and guidance to the emerging options for targeted therapy.

AB - Prostate cancer is the most common and second most lethal cancer in men. The majority of prostate cancers are histologically similar to acinar adenocarcinomas and rely on androgen-dependent signaling for their development and progression. Androgen deprivation therapy is a mainstay of treatment regimens and we discuss the recent advancements in androgen-deprivation therapy. Recent advances in defining the genetic landscape of prostate cancer have shown that the depth of genetic heterogeneity surpasses what can be seen histologically and has the ability to redefine treatments. TMPRSS2-ETS family fusion proteins are unique to prostate cancer and we discuss their role in carcinogenesis, prognosis, and the development of TMPRSS2-ETS family gene fusion targeted therapy. Inactivation of the tumor suppressor PTEN leads to activation of the PI3K/Akt/mTOR pathway and we discuss the prognostic and treatment implications. Molecular genetic analysis has recently demonstrated that clinically aggressive high grade neuroendocrine prostate carcinomas contain a high prevalence of overexpression of Aurora A kinase and N-myc. We discuss the role of Aurora A kinase and N-myc in the development of the aggressive neuroendocrine phenotype and the development of targeted inhibitors of this specific genetic subtype. Lastly, we briefly discuss emerging genetic subtypes defined by either SPINK1 overexpression, CHD1 inactivation, or SPOP mutations. By reviewing the associations between the morphologic features and the molecular genetics of prostate cancer we hope to provide insight and guidance to the emerging options for targeted therapy.

UR - http://www.scopus.com/inward/record.url?scp=84924286936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924286936&partnerID=8YFLogxK

M3 - Article

C2 - 25547910

AN - SCOPUS:84924286936

VL - 16

SP - 103

EP - 114

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 2

ER -